Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DUT | P33316 | 5/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8477470 | 1.00 | LMNA (0.51) | LMNAATML3MBTL1DUTAPOBEC3A | |
| SCHEMBL8481946 | 1.00 | LMNA (0.51) | LMNAATML3MBTL1DUTAPOBEC3A | |
| SCHEMBL8339348 | 0.92 | LMNA (0.53) | LMNAATML3MBTL1DUTCHRM3 | |
| SCHEMBL8342637 | 0.92 | LMNA (0.53) | LMNAATML3MBTL1DUTCHRM3 | |
| SCHEMBL8343216 | 0.92 | LMNA (0.53) | LMNAATML3MBTL1DUTCHRM3 | |
| SCHEMBL20599883 | 0.87 | LMNA (0.49) | LMNAATML3MBTL1DUTCYP2J2 | |
| SCHEMBL20600150 | 0.87 | LMNA (0.49) | LMNAATML3MBTL1DUTCYP2J2 | |
| SCHEMBL8336623 | 0.85 | LMNA (0.56) | LMNAATML3MBTL1DUTCHRM3 | |
| SCHEMBL8339280 | 0.85 | LMNA (0.56) | LMNAATML3MBTL1DUTCHRM3 | |
| SCHEMBL8336619 | 0.85 | LMNA (0.56) | LMNAATML3MBTL1DUTCHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5925666-A | DOPAMINE UPTAKE INHIBITORS; DRUG ABUSE AND DEPENDENCE, EATING DISORDERS, ATTENTION DEFICIT DISORDER, TOURETTE*S SYNDROME, GAMBLING | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-20 | — | — | US | claimed |
| US-11213518-B2 | Ligands of the mu, kappa, and delta opioid receptors | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-5925666-A | DOPAMINE UPTAKE INHIBITORS; DRUG ABUSE AND DEPENDENCE, EATING DISORDERS, ATTENTION DEFICIT DISORDER, TOURETTE*S SYNDROME, GAMBLING | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5650521-A | FOR TREATING COCAINE ADDICTION AND OVERDOSE, AND DISEASES AND CONDITIONS CHARACTERIZED BY ABNORNAL DOPAMINERGIC NEUROTRANSMISSION | GUILFORD PHARMACEUTICALS INC. (US) | 1997-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11213518-B2 | Ligands of the mu, kappa, and delta opioid receptors | OPRK1, OPRD1, OPRM1 | LMNA 3856/4885ATM 4693/4885L3MBTL1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.